Selecting the right therapeutic target for kidney disease
Lisa Buvall(AstraZeneca (United Kingdom)), Pernille Hansen(AstraZeneca (United Kingdom)), Mohammad Bohlooly‐Y(AstraZeneca (Sweden)), Regina Fritsche Danielson(AstraZeneca (United States)), Carolina Haefliger(AstraZeneca (United Kingdom)), Claus Bendtsen(Quantitative BioSciences), Anna Granqvist, Julie Williams(UK Dementia Research Institute), Davide Gianni(AstraZeneca (Germany)), Kevin Woollard(AstraZeneca (United Kingdom)), Robert Menzies(AstraZeneca (Sweden)), Slavé Petrovski(AstraZeneca (United Kingdom)), Chanchal Kumar(Vignana Jyothi Institute of Management), Denis Feliers(AstraZeneca (United Kingdom)), Anna Reznichenko(AstraZeneca (Sweden)), Maria Fritsch(AstraZeneca (Sweden))
Cited by 13
Related Papers
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T <sub>reg</sub> Cell Homeostasis
|Science|2013|5.3k
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
|Science|2009|4.1k
Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis
|Science Signaling|2010|1.5k